Stock Analiz

Cellectis S.A. CLLS

Biotechnology: Pharmaceutical Preparations · IPO 2015 · data as of November 13, 2026

$1.18Market cap $119M
Open the interactive analysis →

Cellectis S.A. (CLLS) is a healthcare company listed in the US with a market value of about $119M. In the twelve months to June 30, 2026 it had revenue of $57M and net income of -$65M, a net margin of -115.4%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 6% a year, a 5-year average ROIC of -57%.

About Cellectis

Cellectis is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2015. Revenue went from $56M in 2016 to $80M in 2025, growth of about 3.9% a year. It was profitable in 0 of the last 10 years in our data.

Score: 1.0 / 5

Value0/5
Future growth4/5
Track record0/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year revenue growth above 8% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S3.7
P/B2.9
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-37.9%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)61.7%
Revenue growth (5 yrs, per year)6.0%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-393.5%
ROIC (5-yr avg.)-57.3%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$57M$80M$49M$9M$26M$39M$60M$23M$21M$34M$56M
Net income-$65M-$68M-$37M-$101M-$106M-$114M-$81M-$102M-$79M-$99M-$67M
Free cash flow-$45M-$42M$20M-$26M-$90M-$123M-$124M-$82M-$73M-$55M-$46M
EPS (diluted)$-0.65$-0.67$-0.37$-1.01$-1.06$-1.14$-0.81$-1.02$-0.78$-0.99$-0.67
Net margin-115.4%-84.9%-74.7%-1099.3%-412.6%-295.9%-136.1%-444.1%-367.2%-294.7%-119.2%
ROIC—-43.3%-45.5%-90.8%-60.1%-46.8%-14.9%-39.2%-25.7%-35.0%-24.7%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 4 analysts is $4.45, 277% above the current price; targets range from $1.30 to $8.00; the consensus rating is “Buy”; expected EPS is $-1.25 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Cellectis pay a dividend?

Not currently.

Is Cellectis a good stock to buy?

We do not give buy or sell advice. Cellectis scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.